Targeted therapy provides ‘phenomenal’ benefit for certain children with glioma

CHICAGO — A combination of two targeted therapies significantly improved outcomes compared with standard care for children with BRAF V600 mutation-positive low-grade glioma, according to study results presented at ASCO Annual Meeting.
Dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) increased response rate, extended PFS and improved clinical benefit rate compared with carboplatin plus vincristine, results of the phase 2/phase 3 study showed.
“We were expecting to see a difference, but the magnitude is phenomenal,” researcher Eric Bouffet, MD, FRCPC, director

CHICAGO — A combination of two targeted therapies significantly improved outcomes compared with standard care for children with BRAF V600 mutation-positive low-grade glioma, according to study results presented at ASCO Annual Meeting.
Dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) increased response rate, extended PFS and improved clinical benefit rate compared with carboplatin plus vincristine, results of the phase 2/phase 3 study showed.
“We were expecting to see a difference, but the magnitude is phenomenal,” researcher Eric Bouffet, MD, FRCPC, director